Emerging Targets for the Treatment of Primary Sclerosing Cholangitis
Seminars in Liver Disease · 2025-09 · 45 (03) · 362-380
DOI: 10.1055/a-2601-9426 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, online erschienen am 26.05.2025. Verfasst von Elisabeth Tatscher und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Molecular Targeted Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 189 Literaturangaben.
Abstract (Originalsprache)
Primary sclerosing cholangitis (PSC) is a rare, progressive cholestatic disease of unknown etiology and characterized by inflammation and stricturing of intrahepatic and/or extrahepatic bile ducts. This process leads to bile duct scarring, progressive liver fibrosis, and end-stage liver disease. PSC is often associated with a specific form of inflammatory bowel disease and patients face a significant risk of developing cholangiocarcinoma and colorectal cancer. The clinical course of PSC can differ significantly between subtypes and affected individuals, representing a major obstacle to successful medical treatment trials. Numerous innovative therapeutic targets have been identified and, at least in part, explored, including nuclear and membrane receptors regulating bile acid metabolism and transport, modulation of gut microbiota, and signaling molecules involved in liver inflammation and fibrosis. Successful drug testing in preclinical PSC models as well as positive signals from some clinical studies justify hope. However, no medical treatment has so far been proven to improve transplant-free survival or overall survival in PSC patients. Disease-modifying drugs are urgently awaited. Despite ongoing efforts to improve study designs and implement treatment trials for novel drug targets, a central breakthrough has not yet been convincingly achieved. This situation might change in the near future. This article summarizes current research efforts aimed at developing medical treatments for PSC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Zitieren
APA
Tatscher, E., Mady, S., & Fickert, P. (2025). Emerging Targets for the Treatment of Primary Sclerosing Cholangitis. Seminars in Liver Disease, 45(03), 362-380. https://doi.org/10.1055/a-2601-9426
Vancouver
Tatscher E, Mady S, Fickert P. Emerging Targets for the Treatment of Primary Sclerosing Cholangitis. Seminars in Liver Disease. 2025;45(03):362-380. doi:10.1055/a-2601-9426
BibTeX
@article{Tatscher2025,
author = {Tatscher, Elisabeth and Mady, Samy and Fickert, Peter},
title = {Emerging Targets for the Treatment of Primary Sclerosing Cholangitis},
journal = {Seminars in Liver Disease},
year = {2025},
volume = {45},
number = {03},
pages = {362--380},
doi = {10.1055/a-2601-9426}
}
EUVIMED